Reading MMSI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MMSI free→Reading MMSI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MMSI free→
NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been steady, and it has a capital-friendly stance. However, the sector backdrop is a headwind, which may affect performance compared to peers, where MMSI trades above typical levels. Peer multiples imply a price about 7% above where it trades (it looks cheap on this basis); the read is fair, quality intact. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $66.53. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $67 MMSI trades at 19× p/e, below its 20× p/e peer median. Our $72 fair value sits above the price; medium confidence. Analysts: $78–$107. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 7% below a flat-multiple fair value, below our forecast of about 11%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.13x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.06 → $0.96 (-8.9% / 30d). 0 raised, 1 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d. 82% of analysts rate Buy.
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$134.
How much price usually moves either way.
On a bad day, this stock has moved -$296.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,718.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Steady growth in operating income shows that the company manages costs well. It also shows good efficiency.
Confirms:Q2 operating income rose year over year, exceeding $44.2M.
Disproves:Q2 operating income declines or stays below $44.2M.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for MMSI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition . On April 30, 2026, Merit Medical Systems, Inc. (“Merit”) issued a press release announcing its operating and financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$78.00 – $107.00 (median $96.00) · 5 analysts · as of 2026-05-01
Roughly priced in line with peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MMSI Merit Medical Systems, Inc. | Above typical Show detailsSector percentile: 87 of 100 | fair | moderate |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 93 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
2 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on strategic acquisitions to enhance product offerings and market position.
Improve operating income through cost management and efficiency improvements.
Focus on increasing gross profit through strategic pricing and cost control.
Why it matters: Acquisitions are key for growth. Success here could boost revenue and market position.
Confirms:A new acquisition will add products or reach more customers.
Disproves:No new acquisitions announced in the next quarter.
Why it matters: Knowing how the acquisition affects finances helps us see its role in growth. This is important for future earnings.
Confirms:A press release or earnings call shows specific revenue or profit from the acquisition.
Disproves:No financial impact details are shared in the next earnings report or press release.
Why it matters: A drop in sector revenue growth could signal broader challenges that affect Merit.
Confirms:Sector revenue growth falls below its median of 10%.
Disproves:Sector revenue growth stays above its median.
Why it matters: Gross profit margin impacts how much money the company makes. A good trend shows good cost control.
Confirms:Gross profit margin improves year-over-year by more than 5%.
Disproves:Gross profit margin goes down each year.
of this Current Report on Form 8-K (including the exhibits attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended, or the Exchange Act. In addition to discl…
Shareholders approved equity incentive and stock purchase plans.